UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/576,816	04/24/2006	Florence Henry	C 2874 PCT/US	9093
23657 FOX ROTHSC	7590 01/09/200 HILD LLP	EXAMINER		
1101 MARKET		MI, QIUWEN		
PHILADELPH	IA, PA 19107		ART UNIT	PAPER NUMBER
			1655	
			MAIL DATE	DELIVERY MODE
			01/09/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/576,816	HENRY ET AL.		
Examiner	Art Unit		

	QIUWEN MI	1655						
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress					
THE REPLY FILED 26 December 2008 FAILS TO PLACE THIS	THE REPLY FILED <u>26 December 2008</u> FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Apper for Continued Examination (RCE) in compliance with 37 Coperiods:	the same day as filing a Notice of A replies: (1) an amendment, affidavi eal (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request					
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire to Examiner Note: If box 1 is checked, check either box (a) or ( MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f)	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE ().	g date of the final rejection FIRST REPLY WAS FII	n. LED WITHIN TWO					
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount of hortened statutory period for reply origithan three months after the mailing dat	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as					
2. The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi AMENDMENTS	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the						
3. The proposed amendment(s) filed after a final rejection, be (a) They raise new issues that would require further cor			cause					
(b) They raise the issue of new matter (see NOTE below (c) They are not deemed to place the application in better appeal; and/or	w);	,	ne issues for					
(d) ☐ They present additional claims without canceling a converse NOTE: (See 37 CFR 1.116 and 41.33(a)).	corresponding number of finally reje	ected claims.						
4. The amendments are not in compliance with 37 CFR 1.12	21 See attached Notice of Non-Co	mpliant Amendment (	PTOL-324)					
5. Applicant's reply has overcome the following rejection(s):		mphant / monament (	102 024).					
6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).								
7. For purposes of appeal, the proposed amendment(s): a) [ how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows:		l be entered and an e	xplanation of					
Claim(s) allowed: <u>none</u> . Claim(s) objected to: <u>none</u> . Claim(s) rejected: <u>12-17,19-21 and 32</u> .								
Claim(s) vithdrawn from consideration: 22-31.  AFFIDAVIT OR OTHER EVIDENCE								
8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).								
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	ıl and/or appellant fail:	s to provide a					
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attach	ed.					
11. $\boxtimes$ The request for reconsideration has bee	n considered but does NOT 1	place the applicati	on in					
condition for allowance because:								
See Continuation Sheet.								
12. Note the attached Information <i>Disclosure Statement</i> (s). (PTO/SB/08) Paper No(s)  13. Other:								
	/Michael V. Meller/							
	Primary Examiner, Art U	nit 1655						

Continuation of 11. does NOT place the application in condition for allowance because: Applicant argues that none of the references teach an extract of the fruit pulp of Argania spinosa to treat damaged skin (page 2, last paragraph; page 3, first five paragraphs). This is not true. The main reference Charrouf et al teach Argan tree (the same as Argania spinosa) produces a fruit called "Argan", which is formed of a fleshy part or pulp and a very hard core containing an oleaginous seed. Argan oil extracted using traditional methods is used in traditional medicine for diseases of the skin, against chickenpox and acne, and against aging of the skin (thus damage of the skin) (page 1, last paragraph bridging page 2). Applicant also argues that the Examiner equates sunscreen uitlity with damaged skin treatment uitlity. (page 4, 2nd paragraph). This is not persuasive. It would have been prima facie obvious for one of ordinary skill in the art at the time the invention was made to use the extract of the plant Argania spinosa to treat skin damage by UV-A and/or UV-B radiation since Charrouf et al (EP 1213025 A1) teach that the extract of the plant Argania spinosa has sunscreen action especially against UV-a and/or UV-B radiation. Thus, Applicant's arguments have been fully considered but they are not persuasive, and therefore the rejections in the record are maintained.